GALLO, CIRO
 Distribuzione geografica
Continente #
NA - Nord America 57
EU - Europa 52
AS - Asia 44
AF - Africa 5
Totale 158
Nazione #
US - Stati Uniti d'America 57
SG - Singapore 24
IT - Italia 20
DE - Germania 16
HK - Hong Kong 11
NL - Olanda 6
CI - Costa d'Avorio 5
CN - Cina 5
RU - Federazione Russa 5
IE - Irlanda 3
AT - Austria 1
FI - Finlandia 1
IL - Israele 1
MM - Myanmar 1
PK - Pakistan 1
TH - Thailandia 1
Totale 158
Città #
Chandler 14
Singapore 14
Naples 12
Hong Kong 11
Santa Clara 8
Ashburn 7
Amsterdam 6
Beijing 2
Council Bluffs 2
Freiburg im Breisgau 2
Gainesville 2
Seattle 2
Afragola 1
Arzano 1
Boston 1
Dublin 1
Falkenstein 1
Kunming 1
Lahore 1
Milan 1
Nanjing 1
Nay Pyi Taw 1
Nuremberg 1
Princeton 1
Rescaldina 1
Tel Aviv 1
Wilmington 1
Totale 97
Nome #
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 43
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC 39
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial 30
A multicenter randomized phase 4 trial comparing sodium picosulphate plus magnesium citrate vs. polyethylene glycol plus ascorbic acid for bowel preparation before colonoscopy. The PRECOL trial 25
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 23
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients 5
Totale 165
Categoria #
all - tutte 1.010
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.010


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202 0 0 0 0 0 0 0 0 0 1 1 0
2021/20226 0 0 0 0 0 0 0 1 2 1 1 1
2022/202337 1 3 0 4 1 4 0 3 4 6 3 8
2023/202456 8 13 11 7 2 0 0 6 1 2 5 1
2024/202560 6 4 0 0 5 15 18 12 0 0 0 0
Totale 165